Allergan Plc (AGN)

175.21
2.20 1.20
NYSE : Health Technology
Prev Close 173.05
Open 174.00
Day Low/High 173.39 / 178.76
52 Wk Low/High 142.81 / 256.80
Volume 2.73M
Avg Volume 2.73M
Exchange NYSE
Shares Outstanding 339.06M
Market Cap 58.22B
EPS -13.20
P/E Ratio N/A
Div & Yield 2.88 (1.64%)

Latest News

Markets Lower on Tuesday: Don't Lose Sight of the Bigger Picture

We are looking to buy into weakness today, even though the market has gotten significantly tougher over the past few days.

Aegon Provides Update On Financial Transformation And Capital Management

Aegon Provides Update On Financial Transformation And Capital Management

Today, at Aegon's first interactive webinar for analysts and investors, CFO Matt Rider will detail the company's ongoing actions to deliver on its financial transformation, approach to capital management and prioritization in capital deployment.

Is Goldman Sachs Going to Be the Next Allergan?

Is Goldman Sachs Going to Be the Next Allergan?

Don't count on it. The fundamentals paint two very different pictures, Cramer says.

Jim's Daily Rundown

Jim discusses Comcast's offer for Fox, Kohl's, Amazon, 3M, JPMorgan, Goldman Sachs, Citigroup and more!

Allergan Continues Active Board Refreshment Process

Allergan Continues Active Board Refreshment Process

- Thomas C. Freyman to Join Allergan plc Board of Directors -

Allergan Announces Positive Topline Phase 3 Clinical Data For Bimatoprost SR (Sustained-Release) Implant For IOP Lowering In Patients With Open-Angle Glaucoma Or Ocular Hypertension

Allergan Announces Positive Topline Phase 3 Clinical Data For Bimatoprost SR (Sustained-Release) Implant For IOP Lowering In Patients With Open-Angle Glaucoma Or Ocular Hypertension

-An investigational implant being developed as the first sustained-release drop-free treatment option for patients-

Stocks Defying Gravity: Cramer's 'Mad Money' Recap (Monday 6/11/18)

Stocks Defying Gravity: Cramer's 'Mad Money' Recap (Monday 6/11/18)

Markets look calm, but we're seeing some extraordinary breakouts, says Jim Cramer.

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

Jim Cramer: Many Reasons Why a Stock Market You Think Should Go Down, Doesn't

You should be thinking positively these days if your stock has had a run or even if it hasn't as a preponderance of good things is liable to happen.

Last Week's Portfolio Changes

We exited one stock, entered another, raised our price target on Kohl's and downgraded Nordstrom.

Weekly Roundup

Markets bathed in the afterglow of the strong jobs report for most of the week.

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.

Dow Jumps Nearly 100 Points as Nasdaq, S&P 500 Slide

Dow Jumps Nearly 100 Points as Nasdaq, S&P 500 Slide

Stocks finished mixed on Thursday as concerns mount over the potential for a major rift on trade and tariffs when G-7 leaders meet later this week.

Allergan And Actress Shay Mitchell Join Forces To Inspire Women To Know Their Birth Control

Allergan And Actress Shay Mitchell Join Forces To Inspire Women To Know Their Birth Control

Know Your Birth Control® Launches New 'BC Trivia' Quiz to Encourage Informed Conversations Around Contraception

Jamie Dimon, Warren Buffett, Allergan and Google - 5 Things You Must Know

Jamie Dimon, Warren Buffett, Allergan and Google - 5 Things You Must Know

U.S. stock futures are higher on Thursday and stocks in Europe and Asia extend gains; Jamie Dimon and Warren Buffett urge companies to consider no longer providing quarterly earnings guidance.

Five Below Tops Expectations and 4 Other Stories to Watch Premarket Thursday

Five Below Tops Expectations and 4 Other Stories to Watch Premarket Thursday

As futures point higher, these are the headlines you need to get up to speed during your morning commute.

Jim Cramer: Tech Can't Do it All Alone

Jim Cramer: Tech Can't Do it All Alone

Tech and retail gains aren't enough to lead markets to new highs.

Allergan Responds To Public Shareholder Letter

Allergan Responds To Public Shareholder Letter

DUBLIN, June 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today issued the following statement in response to a public shareholder letter: Allergan's board of directors and management welcome input from all our shareholders, and take into account...

Jim's Daily Rundown

Jim discusses Constellation Brands, Goldman Sachs and a new position in Salesforce.com.

Allergan Teams Up With A Host Of Celebrities To Encourage Alzheimer's Patients And Their Caregivers To Hold On To Hope

Allergan Teams Up With A Host Of Celebrities To Encourage Alzheimer's Patients And Their Caregivers To Hold On To Hope

The 'Hold on to Hope' movement takes to social media in recognition of Alzheimer's & Brain Awareness during the month of June

Jim's Daily Rundown

Jim discusses our decision to exit Allergan, the AAP Bullpen, Apple's upcoming Worldwide Developers Conference and more!

Exiting Allergan

After a lot of patience and disappointment, we are closing our remaining small 'spec' position.

Weekly Roundup

Markets go through a short and volatile week.

Two Antibiotic Plays

Two Antibiotic Plays

They may not get all the attention, but antibiotic drugs are increasingly important.

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Allergan Pursues Strategic Divestitures; Specialty Retailers Shake Out -- ICYMI

Allergan Pursues Strategic Divestitures; Specialty Retailers Shake Out -- ICYMI

Here's what you need to know now for Wednesday, May 30.

CoolSculpting® And #WeAllGrow Latina Network Host Discussion On The Perceptions Of Beauty And Body In The Latina Community

--Allergan-Sponsored Survey Of Latina Influencers Reveals One In Two Respondants Favor Complementing Diet And Exercise With Non-Surgical Body Contourng Treatments Such As Coolsculpting® [1]--

Allergan Strategic Review is Disappointing

Company's plans to sell two small units are largely a cosmetic fix.

TheStreet Quant Rating: D+ (Sell)